TransMed provides a unique software solution designed to support translational research and personalized medicine.
Greenville, SC (PRWEB) May 29, 2014
Greenville Health System (GHS) which has multiple hospitals and clinics in the state of South Carolina has advanced translational medicine programs focused in oncology which are developed and operated by the Institute for Translational Oncology Research (ITOR). Oncologists affiliated with ITOR and GHS are nationally recognized leaders in the latest advances in molecular oncology. They were one of nine sites in the US chosen to participate in the groundbreaking Bisgrove Study which showed improved outcomes for cancer patients receiving therapy targeted to the molecular characteristics of their tumor over standard of care.
After careful review of the informatics solutions to support their translational medicine initiatives the GHS/ITOR leadership chose TransMed’ s bioinformatics platform. TransMed provides a unique software solution designed to support translational research and personalized medicine. It has been built from the ground up and engineered to address some of the toughest challenges in healthcare information technology.
Features include:
- Unique patent pending connectivity capabilities enabling customers to connect their electronic data systems such as their EMR and lab systems.
- Ability to connect clinical data with molecular data such as gene expression and mutation data from any commercially available systems creating a longitudinal patient record with all clinical and molecular data available for clinical decision making.
GHS/ITOR will deploy the TransMed platform initially to support its bio bank connecting its bio bank IT support platform data with data from the GHS EHR.
